2:04 PM
Sep 12, 2017
 |  BC Extra  |  Company News

Intercept falls on Ocaliva warning for liver-related AEs

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) fell $15.36 (14%) to $98.12 on Tuesday after the company issued a "Dear Health Care Provider" letter warning that liver-related adverse events have been reported in primary biliary cholangitis (PBC) patients receiving Ocaliva obeticholic acid.

Ocaliva is an oral farnesoid X receptor (FXR; NR1H4) agonist that has accelerated approval in the U.S. to treat PBC in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. The drug also has conditional...

Read the full 430 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >